SPDR S&P Biotech ETF
431 hedge funds and large institutions have $5.76B invested in SPDR S&P Biotech ETF in 2018 Q2 according to their latest regulatory filings, with 64 funds opening new positions, 153 increasing their positions, 123 reducing their positions, and 43 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
4.89% more ownership
Funds ownership: 106.36% → 111.25% (+4.9%)
4% more funds holding
Funds holding: 414 → 431 (+17)
28% less call options, than puts
Call options by funds: $1.36B | Put options by funds: $1.9B
Holders
431
Holding in Top 10
22
Calls
$1.36B
Puts
$1.9B
Top Buyers
| 1 | +$194M | |
| 2 | +$175M | |
| 3 | +$120M | |
| 4 |
Goldman Sachs
New York
|
+$98.1M |
| 5 |
SG Americas Securities
New York
|
+$57.2M |
Top Sellers
| 1 | -$192M | |
| 2 | -$102M | |
| 3 | -$78.1M | |
| 4 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
-$71.6M |
| 5 |
NM
NWI Management
New York
|
-$52.6M |